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Ivermectin proposes several potentials effects, with its antimicrobial, antiviral, 
and anti-cancer properties. In a recently published systematic review, 
Ivermectin is effective on several enveloped, positive-sense, single-stranded 
RNA viruses such as Zika Virus, Dengue Virus, Yellow Fever Virus, West Nile 
Virus, Venezuelan Equine Encephalitis Virus, Chikungunya Virus, Semliki 
Forest Virus, Sindbis Virus, Porcine Reproductive and Respiratory Syndrome 
Virus, and Human Immunodeficiency Virus Type 1. Also, SARS-CoV-2 is 
considered as an enveloped, positive-sense, single-stranded RNA virus that was 
inhibited by Ivermectin in in-vitro evaluations. Although several clinical trials 
about the effectiveness of Ivermectin on COVID-19 are on the way, the current 
in vitro research is usually used in the early stages to outline new medications. 
Additionally, further clinical trials are required to confirm the safety and 
efficacy of ivermectin for human use against COVID-19 either therapeutic or 
preventive. We reviewed the vector effects of ivermectin on COVID-19. 
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Ivermectin and COVID-19 
Ivermectin proposes several potentials effects, with its 
antimicrobial, antiviral, and anti-cancer properties. In 
a recently published systematic review, Ivermectin has 
been successful to overcome several enveloped, 
positive-sense, single-stranded RNA viruses such as 
Zika Virus, Dengue Virus, Yellow Fever Virus, West 
Nile Virus, Hendra Virus, Newcastle Virus, 
Venezuelan Equine Encephalitis Virus, Chikungunya 
Virus, Semliki Forest Virus, Sindbis Virus, Avian 
Influenza A Virus, Porcine Reproductive and 
Respiratory Syndrome Virus, and Human 
Immunodeficiency Virus Type 1. Also, SARS-CoV-2 
is considered as an enveloped, positive-sense, single-
stranded RNA virus that was inhibited by Ivermectin 
in in-vitro evaluations (1). It has been revealed that 
ivermectin with a single addition to Vero-hSLAM cells 
two hours post-infection with SARS-CoV-2 could 
affect an almost 5000-fold reduction in viral RNA (2). 
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Although several clinical trials about the effectiveness 
of Ivermectin on COVID-19 are on the way (3), the 
current in vitro research is generally utilized in the 
initial steps to outline new medications. Additionally, 
further clinical trials are required to verify the safety 
and efficacy of ivermectin to be used against COVID-
19 in human beings, either for therapeutic or 
preventive purposes (4). 
In addition to the antiviral effects of Ivermectin 
in in-vitro and in-vivo studies mentioned earlier, the 
Mosquitocidal effects of Ivermectin on viral 
transmission control in some mosquito-borne viruses 
have been investigated. The exact antiviral mechanism 
of Ivermectin was not investigated in these studies. In 
an in vitro study, the injectable form of Ivermectin at a 
dose of 400 mg/kg significantly reduced the 
susceptibility of Culicoides sonorensis (Diptera: 
Ceratopogonidae) to bluetongue virus (BTV)-17, a 
double-strand RNA virus, without a significant effect 
on the mortality rate of this vector. The authors 
concluded that Ivermectin could inhibit BTV-17 in 
Culicoides sonorensis. However, in this study, 
Ivermectin did not significantly alter the rate of 
infection caused by epizootic hemorrhagic disease 
(EHDV) virus, a double-strand RNA virus, in vectors. 
The study aimed to investigate the insecticidal effect of 
this drug on the vector of two viruses, BTV and EHDV, 
called Culicoides sonorensis (5). 
In a study of mosquitoes infected with DENV-2 
called Aedes albopictus, the average infection rate 
followed by Ivermectin doses of 0, 2, 4, 8, 16, 32, and 
64 ng/mL were 84.62%, 85.29%, 82.54%, 74.24%, 
63.33%, 54.29%, and 42.62%, respectively, so that the 
rate of infection decreased with increasing dosage. At 
concentrations above 16 ng/mL, the DENV-2 loads in 
mosquitoes showed a significant decrease. In this study 
for the first time, the researchers acknowledged that 
Ivermectin, directly and indirectly, inhibits DENV-2 in 
mosquitoes (6). 
In another in-vivo and in-vitro study, Nguyen 
and colleagues concluded that Ivermectin-treated bird 
feed could be a new method of controlling WNV 
transmission. In this study, researchers demonstrated 
the effects of Ivermectin as a systemic endectocide in 
birds and suggested the possibility of using Ivermectin 
to control the transmission of WNV. Ivermectin had 
the lowest lethal concentrations resulting in 50% 
mortality (LC50) compared with eprinomectin and 
selamectin, which were 49.94, 101.59, and 151.46 
ng/mL, respectively (7). In another study on FDA-
approved anti-flaviviral drugs, researchers tested the 
mosquitocidal effect against Aedes aegypti and their 
antiviral effect on Zika virus, an enveloped, positive-
sense, single-stranded RNA viruses. They showed that 
Ivermectin had strong adulticidal activity and showed 




The COVID-19 pandemic has had several 
consequences including social inference beyond the 
spread of disease, showing that the international 
community was not ready for this outbreak. Due to 
inadequate researches by international organizations 
and lack of clinical guidelines, there is a long distance 
to reach promising outcomes.  
We do believe that with the potential paucity of 
a vaccine or effective treatment, all potential 
therapeutics should be meticulously explored 
especially the cost-effective ones; Ivermectin is one of 
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